Vascular homing peptides with cell-penetrating properties.
暂无分享,去创建一个
E Ruoslahti | E. Ruoslahti | L. Zhang | T Duza | L Zhang | T. Duza
[1] C. Lehner,et al. Major nucleolar proteins shuttle between nucleus and cytoplasm , 1989, Cell.
[2] Erkki Ruoslahti,et al. Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.
[3] Erkki Ruoslahti,et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. , 2003, Cancer cell.
[4] R. Haubner,et al. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. , 2004, Current pharmaceutical design.
[5] E. Ruoslahti,et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[6] D. Curiel,et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. , 2002, Cancer research.
[7] Erkki Ruoslahti,et al. Targeting the prostate for destruction through a vascular address , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[8] E. Ruoslahti. Specialization of tumour vasculature , 2002, Nature Reviews Cancer.
[9] J. K. Hofmeister,et al. Internalization of anti-nucleolin antibody into viable HEp-2 cells , 2004, Molecular Biology Reports.
[10] E. Ruoslahti,et al. Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[11] E. Ruoslahti. Fibronectin and its receptors. , 1988, Annual review of biochemistry.
[12] D. Hanahan,et al. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. , 2003, Cancer cell.
[13] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[14] E. López-Granados,et al. Cellular Adhesion Mediated by Factor J, a Complement Inhibitor , 1998, The Journal of Biological Chemistry.
[15] R. Longhi,et al. Coupling Tumor Necrosis Factor-α with αV Integrin Ligands Improves Its Antineoplastic Activity , 2004, Cancer Research.
[16] F. Amalric,et al. Fibroblast Growth Factor-2 Binds to the Regulatory β Subunit of CK2 and Directly Stimulates CK2 Activity toward Nucleolin* , 1996, The Journal of Biological Chemistry.
[17] R Pasqualini,et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.
[18] Ülo Langel,et al. Cell-Penetrating Peptides : Processes and Applications , 2002 .
[19] Erkki Ruoslahti,et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels , 2003, The Journal of cell biology.
[20] Erkki Ruoslahti,et al. A tumor-homing peptide with a targeting specificity related to lymphatic vessels , 2002, Nature Medicine.
[21] D. Stolz,et al. Identification of endothelial cell–surface proteins as targets for diagnosis and treatment of disease , 1996, Nature Medicine.
[22] A. O’Brien,et al. Cell Surface-localized Nucleolin Is a Eukaryotic Receptor for the Adhesin Intimin-γ of Enterohemorrhagic Escherichia coliO157:H7* , 2002, The Journal of Biological Chemistry.
[23] S. Nisole,et al. The Anti-HIV Cytokine Midkine Binds the Cell Surface-expressed Nucleolin as a Low Affinity Receptor* , 2002, The Journal of Biological Chemistry.
[24] B. Ding,et al. Lung Endothelium Targeting for Pulmonary Embolism Thrombolysis , 2003, Circulation.
[25] Yan Li,et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy , 2004, Nature.
[26] M. Hirai,et al. Nuclear Targeting by the Growth Factor Midkine , 2002, Molecular and Cellular Biology.
[27] E. Ruoslahti,et al. An address system in the vasculature of normal tissues and tumors. , 2000, Annual review of immunology.
[28] Y. Chen,et al. RGD-Tachyplesin inhibits tumor growth. , 2001, Cancer research.
[29] Wadih Arap,et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. , 2002, Cancer research.
[30] S. Futaki,et al. Possible Existence of Common Internalization Mechanisms among Arginine-rich Peptides* , 2002, The Journal of Biological Chemistry.
[31] Erkki Ruoslahti,et al. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[32] Peter Carmeliet,et al. Molecular mechanisms of lymphangiogenesis in health and disease. , 2002, Cancer cell.
[33] S. Stacker,et al. Molecular targeting of lymphatics for therapy. , 2004, Current pharmaceutical design.
[34] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[35] Erkki Ruoslahti,et al. Organ targeting In vivo using phage display peptide libraries , 1996, Nature.
[36] R. Petryshyn,et al. Effect of laminin on the nuclear localization of nucleolin in rat intestinal epithelial IEC-6 cells. , 1998, Biochemical and biophysical research communications.
[37] D. Brantley-Sieders,et al. Eph receptor tyrosine kinases in tumor and tumor microenvironment. , 2004, Current pharmaceutical design.